IAVI Market Share Analysis for June 2026

What is Marburg virus disease? Understand its history, deadly outbreaks, and the importance of developing vaccines for it.

Health > Health Conditions and Concerns

Domainiavi.org

Year Founded1996

Employees201 - 500

Annual Revenue$100M - $200M

IAVI

IAVI (including company regionals)

iavi.org

See more website traffic and engagement information

IAVI Revenue up to June 2026 is 100M - 200M

revenue generated by IAVI top domains

IAVI top domains revenue over 3 years

Revenue for IAVI top domains

iavi.org100M - 200M

See more with Sales Intelligence

Total visits to IAVI's top domains

Understand IAVI market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

iavi.org26.5K

See more with Sales Intelligence

Avg. visit duration in IAVI's top domains

Analyze IAVI engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

iavi.org00:00:27

See more with Sales Intelligence

Avg. pageviews on IAVI's top domains

See how IAVI keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

iavi.org1.83

See more with Sales Intelligence

IAVI top competitors by domain

Top similar sites in June 2026, ranked by their affinity

novavax.comCompany NameNovavaxEmployees501 - 1000HQUnited States, Maryland, GaithersburgAnnual revenue> $1BTotal visits30.1KFinance > Investing

Top technologies used by IAVI

These are the website technologies, by industry, used by IAVI top domains

Widget (10)

Twemoji

Social (7)

Instagram

Advertising (4)

DoubleClick

Payment & Currencies (4)

PayPal

More Technologies

17

See all

News & Signals from IAVI

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsInternational AIDS Vaccine Initiative, Inc. is developing modified version of the Zaire Ebola vaccine on Jun 2nd '26.IAVI is working on a modified version of the Zaire Ebola vaccine to fight Bundibugyo.

NewsInternational AIDS Vaccine Initiative, Inc. is developing recombinant vesicular stomatitis virus -based vaccine candidate targeting Bundibugyo virus on Jun 1st '26.NEW YORK, NY - JUNE 1, 2026 - IAVI, a global nonprofit biomedical research organization, today announced that it has reached an agreement with The University of Texas Medical Branch (UTMB) allowing IAVI to develop a recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate targeting Bundibugyo virus (BDBV), the orthoebolavirus responsible for the ongoing Ebola epidemic in the Democratic Republic of the Congo (DRC) and Uganda.